Small molecule recognition of disease-relevant RNA structures

Citations Over TimeTop 10% of 2020 papers

Abstract

Targeting RNAs with small molecules represents a new frontier in drug discovery and development. The rich structural diversity of folded RNAs offers a nearly unlimited reservoir of targets for small molecules to bind, similar to small molecule occupancy of protein binding pockets, thus creating the potential to modulate human biology. Although the bacterial ribosome has historically been the most well exploited RNA target, advances in RNA sequencing technologies and a growing understanding of RNA structure have led to an explosion of interest in the direct targeting of human pathological RNAs. This review highlights recent advances in this area, with a focus on the design of small molecule probes that selectively engage structures within disease-causing RNAs, with micromolar to nanomolar affinity. Additionally, we explore emerging RNA-target strategies, such as bleomycin A5 conjugates and ribonuclease targeting chimeras (RIBOTACs), that allow for the targeted degradation of RNAs with impressive potency and selectivity. The compounds discussed in this review have proven efficacious in human cell lines, patient-derived cells, and pre-clinical animal models, with one compound currently undergoing a Phase II clinical trial and another that recently garnerd FDA-approval, indicating a bright future for targeted small molecule therapeutics that affect RNA function.

Related Papers

• → Antibody-enabled small-molecule drug discovery(2012)79 cited
• → Frontier Cities: Encounters at the Crossroads of Empire(2014)8 cited
• → The Wild, Wild Web: The Mythic American West and the Electronic Frontier(2000)24 cited
• Research on Problems concerning Frontier Control of Southwest Territory(2008)
• → Current Status and Strategy of Middle-Molecule Drug Discovery(2022)